Richard Greil

News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
January, 2025
January 2025
M T W T F S S
 12345
6789101112
13141516171819
20212223242526
2728293031  

Richard Greil
Sep 25, 2024, 13:30 | Blog
Matteo Dugo: Neoadjuvant atezolizumab plus chemotherapy in TNBC
Matteo Dugo shared a post on LinkedIn, about recent paper published in Clinical Cancer Research:…
Aug 1, 2024, 03:07 | Insight
PET-adapted BrECADD versus escBEACOPP in Hodgkin Lymphoma
Graham Collins, Associate Professor, Haematology and lymphoma specialist at Oxford Cancer and Haematology centre, shared…
Jul 21, 2024, 21:49 | Blog
Dose-Dense vs Standard Adjuvant Chemotherapy for High-Risk Early Breast Cancer
Yakup Ergün, Medical Oncologist at Antalya City Hospital, shared on X, about a recent paper…
Jul 20, 2024, 17:44 | Insight
Piotr Wysocki: Who should not get dose-dense adjuvant chemotherapy in breast cancer?
Piotr Wysocki recently posted on LinkedIn: "For many years, dose-dense adjuvant chemotherapy has been considered the…
Jul 20, 2024, 10:37 | Blog
Personalized Dose-Dense Adjuvant Chemotherapy for High-Risk Early breast cancer
Ivan R. Gonzalez, Medical Oncologist at Comprehensive Oncology Center, Hospital Angeles Puebla, shared a post…
Jul 19, 2024, 13:20 | Blog
Alexios Matikas: We show for the first time the superiority of dose dense versus Standard Adjuvant Chemotherapy for High-Risk Early Breast Cancer
Alexios Matikas, Associate Professor of Oncology at Karolinska Institute, shared on LinkedIn: "Dose dense is…
Jul 16, 2024, 07:54 | Blog
Michael Hallek: PET-guided BrECADD versus eBEACOPP in Hodgkin lymphoma
Michael Hallek, Director of Clinic I for Internal Medicine and Associated Principle Investigator at the University…
All: 7 Posts: 1 - 100
Special Coverage